First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Final results of the NEPTUN study
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34467
Abstract: Real‐world data on the first‐line treatment of patients with advanced non‐small cell lung cancer (NSCLC) are still limited. The NEPTUN study evaluated effectiveness and safety of first‐line nab‐paclitaxel (Abraxane) plus carboplatin (nab‐P/C) in patients with… read more here.
Keywords: line nab; patients advanced; first line; nab paclitaxel ... See more keywords